Source link : https://www.newshealth.biz/health-news/cardiac-risks-with-newer-psoriasis-meds-match-tnf-inhibitors/
TOPLINE: The newer biologics — interleukin (IL)-17, IL-12/23, and IL-23 inhibitors — demonstrate comparable cardiovascular safety profiles to tumor necrosis factor (TNF) inhibitors in biologic-naive patients with psoriasis or psoriatic arthritis (PsA). METHODOLOGY: In a retrospective cohort study, researchers conducted an emulated target trial analysis using data of 32,098 biologic-naïve patients with psoriasis or PsA […]
Author : News Health
Publish date : 2025-01-07 09:59:07
Copyright for syndicated content belongs to the linked Source.